Rogers Corporation (ROG)
After hours:
| Previous Close | 266.22 |
| Open | 267.82 |
| Bid | 266.00 x 800 |
| Ask | 268.00 x 1000 |
| Day's Range | 267.04 - 268.41 |
| 52 Week Range | 178.43 - 274.51 |
| Volume | |
| Avg. Volume | 157,724 |
| Market Cap | 5.02B |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | 50.36 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 09, 1992 |
| 1y Target Est | N/A |
- Business Wire
Rogers Corporation Reports Second Quarter 2022 Results
CHANDLER, Ariz., August 03, 2022--Rogers Corporation (NYSE:ROG) today announced financial results for the second quarter of 2022.
- Business Wire
Rogers Corporation Reports First Quarter 2022 Results
CHANDLER, Ariz., April 28, 2022--Rogers Corporation (NYSE:ROG) today announced financial results for the first quarter of 2022.
- Business Wire
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., April 04, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new Ocrevus® (ocrelizumab) data that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity will be a platform presentation at the 74th American Academy of Neurology (AAN)
